No Secondary Treatment Failure during Incobotulinumtoxin—A Long-Term Treatment Demonstrated by the Drawing of Disease Severity
The aim of this study was to detect clinical hints regarding the development of secondary treatment failure (STF) in patients with focal dystonia who were exclusively treated with incobotulinumtoxin/A (incoBoNT/A). In total, 33 outpatients (26 with idiopathic cervical dystonia, 4 with Meige syndrome...
Main Authors: | Harald Hefter, Raphaela Brauns, Beyza Ürer, Dietmar Rosenthal, Philipp Albrecht, Sara Samadzadeh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Toxins |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6651/15/7/454 |
Similar Items
-
Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study
by: Harald Hefter, et al.
Published: (2023-06-01) -
“Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study
by: Harald Hefter, et al.
Published: (2023-10-01) -
Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature
by: Sara Samadzadeh, et al.
Published: (2020-08-01) -
The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
by: Sara Samadzadeh, et al.
Published: (2020-12-01) -
The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany
by: Sara Samadzadeh, et al.
Published: (2021-01-01)